Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PRIORITY DRUGS HAVE 7% LONGER MEAN TOTAL DRUG DEVELOPMENT TIME COMPARED TO STANDARD NDAs -- TUFTS REPORT TO HOUSE COMMERCE/OVERSIGHT SUBCOMMITTEE

Executive Summary

The total time between IND filing and NDA approval for priority, or breakthrough, drugs exceeded that for standard drugs by 7% between 1990 and 1994 (8.8 v. 8.2 years, respectively), according to written testimony prepared for a May 25 House Commerce/Oversight Subcommittee hearing by Tufts Center for the Study of Drug Development Associate Director Ken Kaitin, PhD.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel